Skip to main content
. 2011 Aug 9;118(16):4346–4352. doi: 10.1182/blood-2011-01-330738

Table 1.

Characteristics of the 421 patients before HDM/SCT, the 81 patients who died during the first year after HDM/SCT, and the 340 evaluable for response

All (N = 421) (100%) Nonevaluable (N = 81) (19%) Evaluable (N = 340; 81%)
CR vs non-CR, P
CR (N = 145/340) (43%) Non-CR (N = 195/340) (57%)
Median age, y (range) 56 (28-78) 57 (35-76) 56 (28-77) 57 (32-78) .11
Patients ≥ 65 y old, no. (%) 73 (17.3) 15 (18.5) 19 (13) 39 (20) .11
Female sex, n (%) 169 (40) 30 (37) 66 (45.5) 73 (37) .15
Performance status, median (range) 1 (0-3) 1 (0-3) 1 (0-3) 1 (0-3)
No. of organs involved, median (range) 2 (1-6) 3 (1-6) 2 (1-5) 2 (1-6) .13
    1 organ, n (%) 125 (30) 5 (6.2) 46 (32) 74 (38) .07
    2 organs, n (%) 115 (27) 17 (21) 37 (25) 61 (31) .07
    ≥ 3 organs, n (%) 181 (43) 59 (72.8) 62 (43) 60 (31) .07
% with organ involved
    Heart 45 69 36 42 .22
    Kidney 84 86 88 81 .07
    Liver 27 44 31 17 .004*
    Gastrointestinal 20 32 19 16 .56
    Autonomic neuropathy 26 38 24 23 .89
    Peripheral neuropathy 10 7 11 10 .86
    Soft tissue 22 33 17 21 .40
    Lung 4.5 7 4 3.6 .78
% BM plasma cells, median (range) 5 (< 5-25) 5 (5-25) 5 (< 5-20) 10 (2-25) .39
Light chain isotype .004*
    κ, n (%) 81 (19.2) 13 (16) 40 (27.6) 28 (14)
    λ, n (%) 340 (80.8) 68 (84) 105 (72.4) 167 (86)
Time from diagnosis to SCT, months, median (range) 5.2 (1-143) 5 (1-103) 5.5 (1.5-143.5) 5.1 (1.6-132.3) .26
Dose of melphalan, n (%) .007*
    200 mg/m2 231 (55) 27 (33.3) 99 (68.3) 105 (54)
    100-140 mg/m2 190 (45) 54 (66.6) 46 (31.7) 90 (46)
Tandem SCT “per protocol,” n (%) 39 (9.2) 1 (1.2) 9 (6.2) 29 (15) .014*
Follow-up, y, median (range) 4 (0-15.6) 0.2 (0-0.9) 6.9 (1-15.6) 3.9 (1-13.9) < .001*

BM indicates bone marrow; and —, not applicable.

*

Statistically significant.

HHS Vulnerability Disclosure